Metformin promotes the survival of transplanted cardiosphere-derived cells thereby enhancing their therapeutic effect against myocardial infarction
- 1k Downloads
Transplantation of cardiosphere-derived cells (CDCs) has been shown to exert a therapeutic effect in patients with myocardial infarction (MI). However, poor survival of transplanted CDCs limits their beneficial effect. Metformin (MET) activates AMP-activated protein kinase (AMPK) which is associated with cell survival. The aim of this study is to determine whether MET improves CDC survival in the transplantation microenvironment and enhances the therapeutic effect of CDC transplantation against MI.
CDCs were isolated and expanded from transgenic β-actin-GFP mice. CDCs were pretreated with MET and intramyocardially injected into wild-type C57 mouse heart with MI injury. The survival of CDCs was quantified, and the infarct size and cardiac function of treated hearts were evaluated.
CDC transplantation modestly reduced infarct size and improved cardiac function in the post-MI heart, which was further improved by MET treatment. MET pretreatment significantly increased the survival of CDCs transplanted into the myocardium. MET also reduced CDC apoptosis induced by oxidative stress in vitro. The anti-apoptotic effect of MET was blocked by the AMPK inhibitor compound C. MET increased AMPK phosphorylation and upregulated endothelial nitric oxide synthase (eNOS) in CDCs under oxidative stress, which might be associated with the anti-apoptotic effect of MET.
MET improves the survival of transplanted CDCs in the myocardium, thereby enhancing their therapeutic effect against MI injury. The pro-survival function of MET on CDCs might be associated with an AMPK-eNOS-dependent mechanism.
KeywordsMetformin Cardiosphere-derived cells Myocardial infarction AMP-activated protein kinase
Myocardial infarction (MI) is a major severe heart disease that threatens human health worldwide. The substantial loss of functional cardiomyocytes contributes to the pathogenesis of the disease, leading to cardiac failure. Stem cell therapy offers possibilities for restoring lost myocardium and cardiac function. Multiple cell types, including bone marrow-derived cells and adipose tissue-derived cells, have shown modest therapeutic effect on post-MI patients . Another cell type which has been applied to clinical trials is cardiosphere-derived cells (CDCs), which showed protective and regenerative capacity in both post-MI animal models and patients [1, 2]. Autologous CDCs decreased scar size, increased viable myocardium, and improved cardiac function in patients . Transplantation of embryonic stem cell- or induced pluripotent stem cell-derived cells has shown promising effect in post-MI animals [3, 4], although risks of tumorigenesis and arrhythmia currently limit their application in patients.
Irrespective of the cell types used for transplantation, effective cardioprotection and cardiac muscle regeneration are hindered by the poor survival of transplanted cells in the infarcted myocardium, which is high in inflammatory factors and free radicals . Genetic manipulation of pro-survival genes such as prolyl hydroxylase domain protein 2, Akt, Bcl-2, SDF-1, and chemokine receptor 1 have improved the viability of transplanted stem cells in animal studies , but these gene targets are difficult to interfere with in the clinical setting thus far. An alternative approach is to identify a known medicine, which has been used in clinics, to improve the stem cell survival thereby enhancing the therapeutic efficacy.
Metformin (MET), a first-line antidiabetic medication for the treatment of type 2 diabetes, has been reported to inhibit the mitochondrial respiratory chain and activate AMP-activated protein kinase (AMPK). AMPK can stimulate fatty acid oxidation, promote glucose transport, accelerate glycolysis, and inhibit both triglyceride and protein synthesis. AMPK stimulation promotes cardiomyocyte cell survival through a mitochondrial apoptotic mechanism . MET attenuates oxidative stress-induced cardiomyocyte apoptosis and prevents the progression of heart failure in dogs, through a mechanism of activating AMPK . MET also exerts a cardioprotective effect against doxorubicin-induced cardiotoxicity [9, 10]. Furthermore, MET is found to attenuate pulmonary inflammation in animals . Given the anti-apoptotic effect and the potential for reducing inflammation, we here test if MET increases the survival of stem cells in the harsh transplantation environment of the ischemic heart. In the present study, MET treatment was combined with CDC transplantation in the post-MI mouse hearts. The therapeutic effect against MI injury was evaluated, and the underlying mechanisms were further explored.
Male wild-type C57 mice were purchased from the Laboratory Animal Center of Daping Hospital, and transgenic β-actin-GFP mice (C57BL/6-Tg (CAG-EGFP) C14-Y01-FM131Osb) were purchased from the Jackson Laboratory, USA. All experimental procedures using the animals were carried out in accordance with the regulations of the Animal Care and Use Committee of the Third Military Medical University, China. All animal protocols were approved by the Medical Ethics Committee of the Third Military Medical University (Permit Number: 2012). All efforts were made to minimize animal suffering.
Culture and characterization of mouse CDCs
Mouse CDCs with transgenic green fluorescent protein (GFP) labeling were obtained and expanded with a protocol similar to that previously reported . GFP labeling was used for tracing the cell fate of CDCs post-transplantation. Briefly, heart tissues of 4-month-old transgenic β-actin-GFP mice were cut into fragments <1 mm3, washed, and partially digested with trypsin (0.05%; GIBCO). These tissue fragments were cultured as cardiac explants on fibronectin-coated (20 mg/mL; Sigma) dishes in 2 mL cardiac explant media (CEM; Iscove’s modified Dulbecco’s medium (IMDM) supplemented with 20% fetal bovine serum (FBS) and 0.1 mmol/L 2-mercaptoethanol). After a variable period of growth, the loosely adherent cells surrounding the explant (cardiac outgrowth) were harvested using mild enzymatic digestion (0.05% trypsin/EDTA) and dispensed to poly-d-lysine-coated dishes. Several days later, cardiospheres were harvested, plated on fibronectin-coated flasks, and cultured in cardiosphere growth medium (CGM; Dulbecco’s modified Eagle’s medium (DMEM)/F12 supplemented with 35% IMDM, 7% FBS, 29.2 mg/mL l-glutamine, 0.1 mmol/L 2-mercaptoethanol, 2% B27 supplement, 25 ng/mL cardiotrophin, 20 ng/mL basic fibroblast growth factor (bFGF), 10 ng/mL epidermal growth factor (EGF), and 5 U thrombin) to generate CDCs. The characterization of CDCs was investigated by flow cytometry. CDCs were incubated with antibodies against CD29, CD105, CD90, CD31, CD45, and CD34 for 30 min. Isotype-identical antibodies served as a negative control. Quantitative analysis was performed using a BD Accuri™ C6 Cytometer and FlowJo software.
Mouse MI model and intramyocardial injection of CDCs
Animals were randomly allocated into groups with different treatments. The mouse MI model was performed in 4-month-old wild-type C57 mice according to the methods we described previously . Under anesthesia with isoflurane inhalation, permanent ligation of the left anterior descending (LAD) coronary artery was made, and CDCs were injected intramyocardially. The LAD artery was permanently ligated with 7-0 silk suture under direct vision. Sham-operated mice were subjected to the same surgical procedures except with a tied suture. Using a similar protocol to that previously reported , MET was intraperitoneally injected once a day at a dosage of 125 mg/kg for 7 days (the first dose 6 h before MI injury). For cell transplantation, C57 mice were subjected to an intramyocardial injection immediately after MI injury at four points in the infarct border zone with 40 μL phosphate-buffered saline (PBS) containing 1 × 105 CDCs. MET was used to pretreat CDCs (dissolved in PBS at 100 μmol/L containing the CDCs before transplantation) and intraperitoneally injected into the recipient animal.
Echocardiography was performed (GE vivid 7 dimension) to determine cardiac structure and function in anesthetized mice. Mice underwent echocardiography at 4 weeks after surgery. After the induction of anesthesia by inhalation of isoflurane, the hearts were imaged two dimensionally (2D) in long-axis views at the level of the greatest left ventricular (LV) diameter. Left ventricular ejection fraction (LVEF) was automatically calculated by the echocardiography software using Simpson’s method. EF% was calculated as ((LVVd – LVVs)/LVVd) × 100, where LVVd is left ventricular end-diastolic volume (μL) and LVVs is left ventricular end-systolic volume (μL). Left ventricular fractional shortening (FS) was calculated as ((LVDd – LVDs)/LVDd) × 100, where LVDd is left ventricular end-diastolic dimension (mm) and LVDs is left ventricular end-systolic dimension (mm). Echocardiographic data were conducted and analyzed by blinded investigators.
Quantification of CDC survival
To quantify the survival rate of post-transplanted CDCs, heart cells were isolated from the mouse heart at different time points after CDC transplantation using a method of enzymatic digestion . Briefly, heparinized animals were anesthetized and the hearts were rapidly mounted to a langendorff apparatus. The hearts were perfused retrogradely with Ca2+-free normal Tyrode’s solution containing 1 mg/mL collagenase II (Roche) and 0.1 mg/mL protease (Sigma) for about 10 min, depending on digesting conditions. The ventricles were cut off and minced in solution, followed by pipetting to disassociate the cells, and then filtered through a nylon mesh to remove big pieces of undigested tissues. The GFP+ cells represented CDCs or their derived cells, which were carefully counted. The survival rate = 100% × (number of survived GFP+ cells/1 × 105).
Inflammatory cell infiltration analysis
Similar to the method previously described , mouse hearts in the different groups were digested at 48 h after MI. Using a 30-μm filter, the small cells (<30 μm) were collected while most of the cardiomyocytes (>30 μm) were discarded. Inflammatory cell populations were analyzed by BD Accuri™ C6 Cytometer. Representative contour plots were made showing infiltrating monocyte cells in the heart, as defined by the expression of Ly6Chigh and CD11b+. Data were analyzed by FlowJo software.
Hearts were fixed with 4% paraformaldehyde, subsequently embedded in paraffin, and cut to 5-μm thick sections. Similar to the method previously described , quantitative morphometric analysis with Masson’s trichrome staining was performed. The area of infarct size was calculated by dividing the midline length of the infarcted LV wall by the midline length of total LV wall . The percentage of the fibrotic area of the left ventricle was measured using Image J software. Individuals conducting the experiment were blinded to the experimental groups. To observe the survival of GFP+ CDCs in hearts, anti-GFP, anti-sarcomeric tropomyosin (Sigma), and DAPI for nuclei were used to stain the heart tissue. To trace CDC differentiation, immunostaining against GFP, sarcomeric tropomyosin (a cardiomyocyte marker), von Willebrand factor (vWF; an endothelial cell marker), and α-smooth muscle actin (α-SMA; a smooth muscle cell marker) were performed.
The assessment of CDC survival in vitro
CDCs were cultured in serum-free media for 24 h and H2O2 (30 μmol/L for 24 h) was used to induce CDC apoptosis. CDCs were pretreated with MET at different dosages (1, 10, 100, 1000, 3000, or 5000 μmol/L) and for different time periods (15, 30, 60, 120, and 180 min) for inhibiting H2O2-induced CDC apoptosis. Administration of MET at 100 μmol/L for 60 min was selected for the experiment. AICAR (500 μmol/L for 60 min) was used to activate AMPK, and compound C (CC; 20 μmol/L for 4 h) was used for inhibiting AMPK . Cell viability was detected using the CCK8 Cell Proliferation Assay Kit (Dojindo). CCK8 reagent (10 μL) was added to each well and incubated for 2 h at 37 °C. The number of viable cells was calculated by absorbance measurements at 450 nm. For evaluating CDC apoptosis, the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay was undertaken. Apoptosis was also quantified by flow cytometry (FACScan; Dickinson and Company) after cells were stained with annexin V and propidine iodide (PI) by using an AnnexinV-FITC Apoptosis Detection Kit (Sigma) .
Western blot analysis
Total cellular extracts were obtained by cell lysis, as described previously . Briefly, aliquots of cell lysates containing 50 μg protein were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The protein was then transferred from the gel to polyvinylidene fluoride membranes, which were incubated with primary antibodies for 1 h at room temperature and then at 4 °C overnight. After washing with Tris-buffered saline Tween-20, the membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary antibody diluted 1:5000 (Cell Signaling Technology) and the signals were detected by chemiluminescence. Quantification of the bands was carried out using Quantity One software. To ensure equal loading of the protein, GAPDH was used as an endogenous control.
1-Dimethylbiguanide hydrochloride (metformin hydrochloride), 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR; an AMPK activator), 6-(4-(2-piperidin-1-yl-ethoxy)-phenyl)-3-pyridin -4-yl-pyyrazolo(1,5-a) pyrimidine (compound C; an AMPK inhibitor) and H2O2 were purchased from Sigma-Aldrich (USA). Antibodies against phospho-AMPK-Thr-172 and AMPK were purchased from Cell Signaling Technology. The antibodies against endothelial nitric oxide synthase (eNOS) and phospho-eNOS-Ser-1177 were purchased from Santa Cruz Biotechnology.
Data are reported as the mean ± SEM. For analysis of differences between two groups, a student’s t test was performed. For multiple groups, one-way analysis of variance (ANOVA) with post-hoc comparisons by the Tukey’s test was used. Data were analyzed using SPSS 13.0 for Windows (SPSS, Chicago, IL, USA). A P value <0.05 was considered significant.
Characterization of cell phenotypes
To identify the multi-differentiation potential of the CDCs, permanent ligation of the left anterior descending coronary artery was performed to induce MI injury, and CDCs were intramyocardially injected into the infarct border zone. Immunostaining was performed 4 weeks post-transplantation. As shown in Additional file 1 (Figure S1), GFP staining was used to identify the transplanted CDCs, and a few CDCs were demonstrated to express tropomyosin, vWF, or α-SMA, indicating that CDCs could give rise to cardiomyocytes, endothelial cells, and smooth muscle cells, although the differentiation efficacies were very low.
MET augmented the therapeutic effect of CDC transplantation against MI
CDCs were pretreated with MET at 100 μmol/L for 60 min before transplantation. The recipient wild-type C57 mice were randomly assigned to different experimental groups. MI was induced and 1 × 105 CDCs were intramyocardially injected into the infarct border zone immediately after MI. MET treatment was induced by intraperitoneal injection of MET at a dose of 125 mg/kg/day for a week. The initial areas at risk (i.e., the area of ischemia) of the infarcted hearts in the different groups with MI injury were comparable (36.18 ± 1.73%; Additional file 2: Figure S2A). Echocardiography was performed 4 h after MI induction and showed that the post-MI mice had an equivalent reduction in EF% (Additional file 2: Figure S2B).
MET pretreatment promoted CDC survival in post-MI heart
Effects of MET-pretreated CDC transplantation on post-MI myocardial inflammation
MET attenuated oxidative stress-induced CDC apoptosis via AMPK activation
AMPK/eNOS signaling pathway mediated the pro-survival effect of MET on CDCs
Much progress has been made in the field of stem cell transplantation for treating MI, but challenges such as poor cell survival in the harsh transplantation microenvironment greatly limit its therapeutic effect. In this study, we combined MET treatment and CDC transplantation for treating MI injury in mice, and found that MET improved CDC survival thereby enhancing its therapeutic effect after transplantation. Our data showed that the anti-apoptotic function of MET on CDCs was associated with AMPK activation and eNOS phosphorylation. Since MET is a safe medication in clinical practice, combination of MET treatment with stem cell therapy is of clinical significance to treat MI patients.
The fact that CDC transplantation elicits cardioprotective effects has been shown in small and large animals, and in patients with MI injury. Aside from autologous CDC transplantation, ‘off-the-shelf’ allogeneic human CDCs are being tested clinically in the ALLSTAR and DYNAMIC trials . CDCs have multi-differentiation capacity in vivo, which was confirmed in our study. It is also known that the therapeutic effect of CDCs is mainly mediated by the paracrine effect rather than by direct differentiation [18, 19]. CDCs were reported to stimulate increased myocyte proliferation compared with other stem cell types such as bone marrow-derived mesenchymal stem cells , probably because CDCs exhibited a balanced profile of paracrine factor production . The effects of both the paracrine effect and differentiation rely on the quantity of the surviving CDCs. In our study, we speculate that these functions of CDCs were improved when more post-transplanted CDCs survived with MET treatment. The reduced infarct size might be due to decreased myocyte apoptosis and increased new cardiomyocyte formation.
Despite the progress in recent years, the survival of transplanted cells in infarcted myocardium is still poor [5, 22]. Previous studies reported that only <5% of post-transplanted stem cells survive in the peri-infarct area. Factors such as ischemia, oxidative stress, and inflammation hamper stem cell survival in the post-MI heart. MET is reported to attenuate inflammation , but our data indicated that the pro-survival effect of MET on CDCs in the infarcted heart was less likely associated with its influence on inflammation. Oxidative stress alters the balance of the production and elimination of intracellular oxygen-free radicals and results in over-accumulation of reactive oxygen species (ROS), which are major factors inducing the apoptosis of transplanted stem cells . Efforts including modification of cell survival-associated genes have been made , but these methods are far from clinical use. We demonstrated that MET pretreatment exerted an anti-apoptotic effect on CDCs subjected to oxidative stress in vitro, and that MET promoted the survival of post-transplantation CDCs in vivo. The combination of MET and CDC transplantation exerted a significantly greater effect on increasing cardiac function and reducing infarct size of the infarcted heart, indicating that MET is a ready-to-use medication for augmenting the therapeutic effect of stem cell transplantation.
MET is recognized to activate AMPK, which is essential for keeping the balance of energy production and metabolism in various tissues, thereby modulating cell apoptosis. MET can also exert cardioprotective effects independently of anti-hyperglycemic effects. MET-induced AMPK activation exerts protective effects against acute oxidative stress-induced injury in cardiomyocytes . AMPK works as a protein kinase to activate eNOS by phosphorylating eNOS at Ser-1177 . As a potent protective signaling molecule, eNOS is expressed in vascular endothelial cells, cardiomyocytes, and different types of stem cells. Overexpression of eNOS generates low amounts of NO, which regulates the apoptosis of embryonic stem cells . MET improves cardiomyocyte survival under ischemia/perfusion injury, which is associated with increases in AMPK and eNOS phosphorylation . We demonstrated that MET increased AMPK and eNOS phosphorylation in CDCs. Another AMPK activator, AICAR, showed similar effects to MET. These data suggest that the MET-induced anti-apoptotic effect on CDCs might be associated with the AMPK/eNOS pathway.
Our study reveals that MET treatment significantly enhances the therapeutic effect of CDC transplantation against MI injury. The pro-survival effect of MET on CDCs might be through an AMPK-eNOS-dependent mechanism. Since MET is a safe and ready-to-use medication, combination of MET treatment and stem cell therapy may be a promising strategy in clinical practice.
This study was supported by research grants from the National Natural Science Foundation of China (81670277) and the National Basic Research Program of China (2013CB531104).
Availability of data and materials
The datasets supporting the results of this article are included within the article.
CZ and WEW conceived the project and designed the experiments. RY, WF, XL, LL, QL, DY, XX, and CL conducted experiments. RY wrote the manuscript. WEW, CZ, and XC revised the manuscript. All authors reviewed the manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
All authors read and approved the final manuscript.
Ethical approval and consent to participate
All animal protocols were approved by the Medical Ethics Committee of the Third Military Medical University (Permit Number: 2012).
- 1.Malliaras K, et al. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J Am Coll Cardiol. 2014;63:110–22.CrossRefPubMedGoogle Scholar
- 5.Li L, et al. How to Improve the Survival of Transplanted Mesenchymal Stem Cell in Ischemic Heart? Stem Cells Int. 2016;4:1–14.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.